Adding tucatinib to trastuzumab (Herceptin) and capecitabine (Xeloda) reduced the risk of death by 34% in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.
An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.
The FDA has approved Cologuard Plus, a next-generation multitarget stool DNA test, for adults at least 45 years of age who are at average risk…
Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.
Maria Vittoria Dieci, MD, discusses the prognostic value of tumor-infiltrating lymphocytes in patients with early HER2-positive breast cancer.
MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.
Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.
Serum MPO, CEACAM1 positivity, and PD-L1 CPS could predict benefit with CM24-based therapy in second-line pancreatic ductal adenocarcinoma.
The FDA has approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for newly diagnosed, transplant-ineligible myeloma.
The European Commission has approved frontline zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric and GEJ cancer.
The EMA’s CHMP has recommended the approval of subcutaneous daratumumab plus VRd in patients with newly diagnosed, transplant-eligible multiple myeloma.
